These are top 10 stocks traded on the Robinhood UK platform in July
David Badawi, Chief Technology Officer at Sight Sciences , Inc. (NASDAQ:SGHT), recently sold 3,829 shares of the company's common stock. The shares were sold on January 8 at a price of $3.259 each, amounting to a total value of $12,478. The transaction comes as the stock trades near its 52-week low of $3.20, having declined 46% over the past six months. According to InvestingPro analysis, the company maintains a strong liquidity position, holding more cash than debt on its balance sheet. Following this transaction, Badawi holds 1,749,541 shares directly. The sale was executed to cover tax liabilities related to the vesting of restricted stock units. InvestingPro subscribers have access to 12 additional key insights about SGHT, including detailed analysis of its financial health and comprehensive valuation metrics. Get the full picture with the Pro Research Report, available for 1,400+ US stocks.
In other recent news, Sight Sciences Inc. has been making notable strides in both its financial performance and technological advancements. A study published in the American Journal of Ophthalmology highlighted the effectiveness of the company's OMNI Surgical System in reducing intraocular pressure in patients with primary open-angle glaucoma. The company, which generates an annual revenue of nearly $80 million, also secured an additional $5 million in loan funding from its existing credit facility with Hercules Capital (NYSE:HTGC), Inc., bringing the total borrowed amount to $40 million.
Sight Sciences reported a 1% year-over-year increase in third-quarter revenue, reaching $20.2 million, despite an 8% sequential decrease in surgical glaucoma revenue and a 4% decline in dry eye revenue. UBS initiated coverage of Sight Sciences with a Buy rating, forecasting strong sales growth by 2026. The UBS analyst expects the company's TearCare Dry Eye solution to drive double-digit sales growth and gross margin expansion that exceeds consensus estimates for 2026 and beyond.
Sight Sciences remains optimistic about growth in the surgical glaucoma and dry eye segments in 2025, despite current setbacks. The company is contesting the final 2025 Medicare payment rule, which did not grant device-intensive status to OMNI procedures. These are the recent developments in the company's operations and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.